Complete Versus Lesion-only Primary PCI Pilot Study

Conditions

ST elevation myocardial infarction (STEMI) Circulatory System Myocardial infarction

Anthony Gershlick, Amerjeet Banning, Emma Parker, Duolao Wang, Charley Budgeon et al. (12 authors)

Journal of the American College of Cardiology2019-12-0158 citations

10.1016/j.jacc.2019.10.033

Infarct size and left ventricular remodelling after preventive percutaneous coronary intervention.

Mangion K, Carrick D, Hennigan BW, Payne AR, McClure J, Mason M, Das R, Wilson R, Edwards RJ, Petrie MC, McEntegart M, Eteiba H, Oldroyd KG, Berry C.

2016-08-0810 citations

10.1136/heartjnl-2015-308660

Infarct Size Following Treatment With Second‐ Versus Third‐Generation P2Y <sub>12</sub> Antagonists in Patients With Multivessel Coronary Disease at ST‐Segment Elevation Myocardial Infarction in the CvLPRIT Study

Jamal Nasir Khan, John P. Greenwood, Sheraz A. Nazir, Florence Lai, Miles Dalby et al. (15 authors)

Journal of the American Heart Association2016-06-0149 citations

10.1161/jaha.116.003403

Relationship of Myocardial Strain and Markers of Myocardial Injury to Predict Segmental Recovery After Acute ST-Segment–Elevation Myocardial Infarction

Jamal Nasir Khan, Sheraz A. Nazir, Anvesha Singh, Abhishek Shetye, Florence Lai et al. (9 authors)

Circulation Cardiovascular Imaging2016-06-0127 citations

10.1161/circimaging.115.003457

Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study

Jamal Nasir Khan, Sheraz A. Nazir, John P. Greenwood, Miles Dalby, Nick Curzen et al. (16 authors)

Journal of Cardiovascular Magnetic Resonance2016-01-0116 citations

10.1186/s12968-016-0298-2

The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR)

Gerry P McCann, Jamal Nasir Khan, John P. Greenwood, Sheraz A. Nazir, Miles Dalby et al. (16 authors)

Efficacy and Mechanism Evaluation2016-01-011 citations

10.3310/eme03010

Complete Versus Lesion-Only Primary PCI: The Randomized Cardiovascular MR CvLPRIT Substudy.

McCann GP, Khan JN, Greenwood JP, Nazir S, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman DJ, Ring A, Ring A, Peebles C, Wong J, Sasikaran T, Flather M, Swanton H, Gershlick AH.

2015-12-0144 citations

10.1016/j.jacc.2015.09.099

Interventions

Primary percutaneous coronary intervention in patients with multi-vessel coronary disease randomised to a strategy of early multi-vessel revascularisation or infarct related artery revascularisation o

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Registry: 1. Suspected or proven acute myocardial infarction 2. Significant ST elevation on electrocardiogram (ECG) 3. Less than 12 hours of symptom onset 4. Scheduled for primary percutaneous coronary intervention (PCI) for clinical reasons 5. Provision of verbal assent followed by written informed consent RCT: 1. Suspected or proven acute myocardial infarction 2. Significant ST elevation on ECG 3. Less than 12 hours of symptom onset 4. Scheduled for Primary PCI for clinical reasons 5. Provision of verbal assent followed by written informed consent 6. Multivessel coronary disease detected at time of angiography

Exclusion criteria

Exclusion criteria: Registry: There are no formal exclusion criteria for the CVLPRIT registry for patients that meet the inclusion criteria. RCT: 1. Any contraindication to PPCI or multi-vessel PPCI 2. Less than 18 years age 3. Clear indication for or contraindication to multivessel PPCI, according to operator judgement and the reasons will be documented 4. Severe kidney impairment

Design outcomes

Primary

Measure	Time frame
Cumulative major adverse cardiovascular events (MACE): all-cause mortality, recurrent MI, heart failure, need for revascularisation (PCI or CABG), measured up to 12 months	—

Secondary

Measure	Time frame
1. Individual components of primary composite outcome 2. Safety: Emergency coronary artery bypass graft (CABG), confirmed stroke, major bleeding, surgical repair of vascular complications, up to 12 months 3. Number of patients presenting with PPCI with significant micro vessel density (MVD) 4. Ischaemic burden at 6-8 weeks (expressed as % of total) by MPS 5. Economic assessment and cost efficacy including days in hospital at 12 months 6. Contrast induced nephropathy (rise Cr greater than 25%) or 44.2 umol/l within 48 hours persisting greater than or equal to 48 hours 7. Change in NT-ProBNP from pre-discharge to 12 months 8. Echocardiographic left ventricular ejection fraction (LVEF) and wall motion score (discharge and 12 months) 9. Quality of Life Score at 12 Months (EuroQol questionnaire) 10. Infarct size, extent of microvascular obstruction, myocardium salvaged, left Ventricular (LV) volumes and ejection fraction (EF) at discharge by CMR and new myocardial injury and volumes at 9 - 12 months	—

Measure

Time frame

1. Individual components of primary composite outcome 2. Safety: Emergency coronary artery bypass graft (CABG), confirmed stroke, major bleeding, surgical repair of vascular complications, up to 12 months 3. Number of patients presenting with PPCI with significant micro vessel density (MVD) 4. Ischaemic burden at 6-8 weeks (expressed as % of total) by MPS 5. Economic assessment and cost efficacy including days in hospital at 12 months 6. Contrast induced nephropathy (rise Cr greater than 25%) or 44.2 umol/l within 48 hours persisting greater than or equal to 48 hours 7. Change in NT-ProBNP from pre-discharge to 12 months 8. Echocardiographic left ventricular ejection fraction (LVEF) and wall motion score (discharge and 12 months) 9. Quality of Life Score at 12 Months (EuroQol questionnaire) 10. Infarct size, extent of microvascular obstruction, myocardium salvaged, left Ventricular (LV) volumes and ejection fraction (EF) at discharge by CMR and new myocardial injury and volumes at 9 - 12 months

—

Countries

United Kingdom

Outcome results

None listed